Bristol Myers Squibb Trails Novo Nordisk on Profit Margin
Bristol Myers Squibb and Novo Nordisk posted similar revenue in the 12 months through September 2026, but Novo reported a substantially higher net margin. The drugmakers face different pressures, including US drug-price negotiations, patent expirations and competition in obesity treatments.

Bristol Myers Squibb reported a lower profit margin than Novo Nordisk despite similar revenue in the 12 months ended September 30, 2026. The figures show contrasting earnings profiles as both drugmakers face pricing and competitive pressures.
Bristol Myers recorded approximately $50.0 billion in revenue, up roughly 4.2% from the previous year. Net income was approximately $9.2 billion, with a net margin of roughly 18.5%.
Novo reported about $49.0 billion in revenue, an increase of approximately 5.7%. Its net income was around $16.6 billion, and its net margin was roughly 33.9%.
Bristol Myers develops treatments for cancer, blood disorders and neurological conditions. Its collaborations include Johnson & Johnson, Zai Lab and Merck & Co.
Most of its sales go through wholesalers and distributors. Its three largest US wholesalers account for a substantial portion of global gross revenue, leaving the company exposed to those customer relationships.
Novo focuses on chronic diseases, particularly obesity and diabetes. It also operates in rare blood and endocrine disorders across the United States, Europe and China. Demand for Ozempic and Wegovy supports its profitability.
The companies also differ in their balance sheets. As of December 2025, Bristol Myers had a debt-to-equity ratio of nearly 2.6 times, compared with roughly 0.7 times for Novo.
That ratio compares debt with shareholder equity. Their current ratios, which compare short-term assets with short-term liabilities, were roughly 1.3 times for Bristol Myers and nearly 0.8 times for Novo.
For the fiscal year ended December 31, 2025, Bristol Myers reported approximately $12.8 billion in free cash flow. Novo reported approximately $4.3 billion.
Bristol Myers faces pricing pressure and reimbursement restrictions under the US Inflation Reduction Act. The law has led to government-set prices for Eliquis and Pomalyst, while upcoming negotiations for Orencia could pressure revenue.
The company also faces the loss of market exclusivity for Eliquis, Opdivo and Revlimid. Generic competition could reduce revenue from those products.
Novo faces competition in obesity treatments from Eli Lilly & Co. and Pfizer. It must also contend with US pricing pressure and demand for manufacturing capacity for Wegovy and Ozempic.
Analysts expect Novo's sales to decline about 3% in fiscal 2026 and net income to fall 4%. They expect growth to resume as new products come online.
Bristol Myers' current fiscal-year revenue is expected to rise 3% to $49.8 billion. Net income is expected to rise more than 40% to $11.2 billion.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Markets · FintechHow to Calculate Compound Interest: Formula, Examples and the Rule of 72
Lifestyle · Food & HealthNormal Blood Pressure Chart by Age: Healthy Ranges Explained
Lifestyle · Food & HealthWhat Is Raynaud’s Syndrome? Why Fingers Turn White in the Cold
Lifestyle · Food & Health4 Ways Walking After Meals Helps Your Body, Doctors Say




















